Mesoblast (MESO) Cash from Investing Activities (2016 - 2023)
Mesoblast (MESO) posted Cash from Investing Activities of $16000.0 for Q2 2023, down 40.74% sequentially from $27000.0 in Q1 2023, and up 134.04% YoY from $6836.4 in Q2 2022.
Mesoblast (MESO) Cash from Investing Activities (2016 - 2023) Analysis & Trends
Mesoblast has reported Cash from Investing Activities for 8 years, with the latest figure at $16000.0 in Q2 2023.
- Quarterly Cash from Investing Activities rose 134.04% year-over-year to $16000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$194000.0 (up 16.38% YoY) and the FY2025 annual result came in at $120000.0, up 223.71% from the prior year.
- Cash from Investing Activities retreated to $16000.0 in Q2 2023 per MESO's latest filing, from $27000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $27000.0 in Q1 2023 and troughed at -$1.9 million in Q2 2020.
- A 5-year average of -$346333.3 and a median of -$151000.0 in 2021 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2020 and 2023: Cash from Investing Activities slumped 670.0% in 2020, then surged 148.21% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$459000.0 in 2019, then gained by 11.33% to -$407000.0 in 2020, then soared by 92.63% to -$30000.0 in 2021, then declined by 13.33% to -$34000.0 in 2022, then jumped by 147.06% to $16000.0 in 2023.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $16000.0, $27000.0, and -$34000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 16,000.00 |
| Jun 30, 2023 | 16,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | -34,000.00 |
| Dec 31, 2022 | -34,000.00 |
| Sep 30, 2022 | -203,000.00 |
| Sep 30, 2022 | -203,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Dec 31, 2021 | -30,000.00 |
| Sep 30, 2021 | -99,000.00 |
| Sep 30, 2021 | -99,000.00 |
| Jun 30, 2021 | -223,000.00 |
| Jun 30, 2021 | -223,000.00 |
| Mar 31, 2021 | -936,000.00 |
| Mar 31, 2021 | -936,000.00 |